The partner of Russia's Sputnik V vaccine in Turkey, Viscoran Health Science, Chairman of the Board of Directors Öztürk Oran, in his written statement;

Following the authorization of Sputnik V vaccine, the first registered vaccine in Russia, another innovation has been announced. It was revealed that the first dose of Sputnik V, rAd26, which was developed at the Gamaleya Research Institute, demonstrated 79.4% efficacy. This new product, developed under the name of "Sputnik Light", is the first component of Sputnik V, it is a single dose and was licensed in Russia last Friday.

Our company, which received emergency use approval for Sputnik V from the Ministry of Health TITCK, will now apply to the Ministry of Health TITCK immediately to bring "Sputnik Light" to our country.